ArticleScientific reports2026
Identification and verification of SPP1 in anoikis as a prognostic biomarker for intestinal metaplasia and gastric cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Anoikis is a form of apoptosis induced by cell detachment from the extracellular matrix, and cancer cells must evade it to metastasize. Gastric cancer (GC) remains a leading global cause of cancer-related mortality, with intestinal metaplasia (IM) established as a key premalignant lesion. This study explored the multi-omics features of the anoikis-related gene SPP1 across the control-IM-GC cascade, focusing on its links to immunity and prognosis. Comprehensive transcriptome analyses were conducted using datasets from The Cancer Genome Atlas (TCGA), the Gene Expression Omnibus (GEO), and the GeneCards database via the R programming language. By integrating Weighted Gene Co-expression Network Analysis (WGCNA) and competing endogenous RNA (ceRNA) networks, alongside Gene Set Variation Analysis (GSVA) and Gene Set Enrichment Analysis (GSEA), the study explored the immunological roles of Secreted Phosphoprotein 1 (SPP1) in GC. Furthermore, immune infiltration and immune checkpoint analyses were combined with single-cell RNA sequencing (scRNA-seq) to elucidate the tumor microenvironment. Finally, Cox proportional hazards regression and Receiver Operating Characteristic (ROC) curve analyses were utilized to assess the prognostic significance of SPP1 and to construct a predictive risk signature. RT-qPCR/Western blot (32 human tissues) and in vitro assays were conducted to validate SPP1's expression and function. SPP1 was significantly upregulated across the Correa cascade, with high predictive accuracy, and was associated with survival and potential immunotherapy relevance. Higher levels were associated with a poorer prognosis. In vitro, SPP1 inhibition reduced GC cell migration, enhanced apoptosis, and induced S/G2 phase arrest. To our knowledge, this is the first study to associate SPP1 with IM/GC. Our findings suggest that it may serve as a prognostic biomarker, with immunotherapeutic implications that require further study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.